Actinium Pharma (ATNM) Prices 8M Common Stock Offering at $1.25/Share

September 29, 2016 8:17 AM EDT
Get Alerts ATNM Hot Sheet
Trade ATNM Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $1.25. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about October 4, 2016, subject to customary closing conditions.

The gross proceeds to Actinium from this offering is expected to be $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Actinium. Actinium currently intends to use the net proceeds from the sale of securities for general corporate purposes, including capital expenditures, the advancement of its drug candidates in clinical trials, such as Iomabâ„¢-B and Actimabâ„¢- A, preclinical trials, and to meet working capital needs.

H.C. Wainwright & Co. is acting as sole book-running manager for the offering. JonesTrading Institutional Services LLC is acting as co-manager for the offering. ROTH Capital is acting as a financial advisor for the offering.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Equity Offerings, Hot Corp. News

Related Entities

Roth Capital, H.C. Wainwright

Add Your Comment